c-RET
The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively. Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.
c-RET 相关产品(7)
- GC10111RegorafenibCAS: 755037-03-7纯度: >99.00%
Regorafenib是一种具口服活性的多激酶抑制剂,抑制VEGFR1/2/3,PDGFRβ,Kit,RET和Raf-1的IC 50 值分别为13/4.2/46,22,7,1.5和2.5nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC10035 | TG101209 | 936091-14-4 | >99.50% | |
An inhibitor of JAK2, FLT3, RET, and JAK3 | ||||
| GC10111 | Regorafenib | 755037-03-7 | >99.00% | |
Regorafenib是一种具口服活性的多激酶抑制剂,抑制VEGFR1/2/3,PDGFRβ,Kit,RET和Raf-1的IC 50 值分别为13/4.2/46,22,7,1.5和2.5nM。 | ||||
| GC14534 | Regorafenib monohydrate | 1019206-88-2 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14606 | Regorafenib hydrochloride | 835621-07-3 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC15217 | Danusertib (PHA-739358) | 827318-97-8 | >98.50% | |
A pan-Aurora kinase and Abl inhibitor | ||||
| GC15307 | SU5416 | 204005-46-9,194413-58-6 | >98.00% | |
SU5416 是一种有效的小分子血管内皮生长因子受体 (VEGFR) 抑制剂。 | ||||
| GC16391 | Amuvatinib (MP-470, HPK 56) | 850879-09-3 | >98.00% | |
A multi-targeted RTK inhibitor | ||||
